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carriers for liver targeting
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aDepartment of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi. Oxford, MS. 38677, USA.
bResearch Institute of Pharmaceutical Sciences, The University of Mississippi. Oxford, MS. 38677, USA.
PURPOSE
The objective of the present study was to prepare and characterize a
sterylamine-lactobionic acid (SALB) attached nanostructured lipid carrier
(NLC) system of NPC1161B (NPC; SALB-NPC-NLC) that might improve
the liver uptake for the treatment of malaria.
.
CONCLUSION
•Ligand attached NPC-NLC formulations were successfully prepared with desired physicochemical
properties and were stable for up to 30 days.
•Further optimization and studies with respect to liver targeting needs to be done.
METHOD(S)
Preparation of SALB-NPC-NLC formulations: Homogenization
followed by sonication method was used for the preparation of SALB-
NPC-NLC formulations (Table 1). The drug, solid lipid, liquid lipid and co-
surfactant were dissolved and maintained at 5oC above the melting point
of the solid lipid. The aqueous phase containing the SALB and surfactant
was maintained at the same temperature. Then, the hot aqueous phase
was added to lipid phase followed by homogenization at 16000 rpm for 5
min, using Ultra-Turrax T25 (IKA, Germany). The coarse dispersion thus
formed was subjected to probe sonication (Sonics, USA) for 10 min at
40% amplitude with 10-second pulse off and 20-second pulse on.
Table 1:Composition table of SALB-NPC-NLC optimized formulations
Characterization of SALB-NPC-NLC formulations:
Particle size, zeta potential (ZP), and polydispersity index (PDI): The
hydrodynamic radius, PDI and ZP of the NLC formulations were
determined by photon correlation spectroscopy, using Zetasizer Nano ZS
Zen3600 (Malvern Instruments, Inc.) at 25°C.
Assay: Drug content of the SALB-NPC-NLC formulations were estimated
using HPLC method.
Entrapment Efficiency (EE):The EE was measured by an ultrafiltration
technique with a 100 kDa centrifugal filter device (Amicon Ultra, USA),
using HPLC method.
Stability study: Physical and chemical stability of SALB-NPC-NLC
formulations were evaluated for one month (last time point checked) at
4°C and 25°C.
BACKGROUND
• NPC is a new 8-aminoquinoline derivative from primaquine with improved
therapeutic effect. It is used in late preclinical development for the treatment
of malaria.
• 8-aminoquinolines are known to have dose limiting hemolytic toxicity in
individuals with glucose-6-dehydrogenase phosphate deficiency and to
overcome this problem, the 8-aminoquinolines a lipid based nanoformulation
is being proposed.
• Ligand, SALB, is specifically used to target asyloglycoprotein receptors,
which are primarily expressed in hepatocytes and would thus give a liver
targeted delivery.
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Ingredients (%w/v) SALB-NPC-NLC-1 SALB-NPC-NLC-2
NPC 1161B 1.2 1.2
Compritol ATO 888 4.5 4.5
Castor oil 1.5 1.5
Tween 80 1.5 1.5
Poloxamer 188 0.25 0.25
Glycerin 2.25 2.25























Figure 1:Particle size of SALB-NPC-NLC 
formulations at room temperature (RT) and 
refrigerated temperature (RF) over one month (mean 









Day 1 Day 30
Figure 2:PDI of SALB-NPC-NLC formulations at room 
temperature (RT) and refrigerated temperature (RF) 













Day 1 Day 30
Figure 3: ZP of SALB-NPC-NLC formulations at room 
temperature (RT) and refrigerated temperature (RF) 












Day 1 Day 30
Figure 4: EE (%) of SALB-NPC-NLC formulations at room 
temperature (RT) and refrigerated temperature (RF) over 













Day 1 Day 30
Figure 5: Assay (%) of SALB-NPC-NLC formulations at room 
temperature (RT) and refrigerated temperature (RF) over one 
month (mean ± SD, n = 3). 
RESULTS:
•Formulations with particle size less than 300
nm were prepared which is required as, RES
of liver and spleen usually remove particles
with size more than 300 nm.
•Optimized SALB-NPC-NLC formulations
were found to be stable physically and
chemically at room and refrigerated conditions
for one month.
•High ZP was achieved which is a good
indicator for stability of formulation.
•EE of around 88% was achieved without any
significant decrease in one month.
RESULTS
